http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2367876-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92c919237cd10f437e2e29529230052a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D225-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D225-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12 |
| filingDate | 2007-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47a1be82be47fe4d4b44d89d1e01e6f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d918bdb5b688e61c3ad0575eeed9bcd1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c3e1ca9bd409c9d3c7ea601c6b52fde http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97917de8226a8b0a7bbd3f7d490b7e56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5eae11578ff7537de508d01ff40370eb |
| publicationDate | 2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2367876-T3 |
| titleOfInvention | DERIVATIVES OF 18-AMINO ANALOGS REPLACED FROM GELDAMICINE HYDROQUINONE WITH CYTOTOXIC ACTIVITY FOR CANCER TREATMENT. |
| abstract | Compound or pharmaceutically acceptable salt thereof having the formula (I) in which - X is selected from the group consisting of -N (R8) (R9), -N (R8) -C (O) R10, -N ( R8) -C (O) -OR10, -N (R8) -SO2R10, N (R8) -C (O) -NR8R10, -N (R8) -C (S) OR10, -N (R8) -C ( S) -OR10 and -N (R8) -C (S) -NR8R10; wherein R8 and R9 are independently selected from the group consisting of H, optionally substituted (C1-C20) alkyl, optionally substituted heteroalkyl (C2-C20), optionally substituted alkenyl (C2-C20), optionally substituted heteroalkenyl (C2-C20) optionally substituted, optionally substituted (C2-C20) alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkyl, and optionally substituted cycloheteroalkyl or R8 and R9 together with the nitrogen to which they are attached form a ring optionally substituted 4-7 membered heterocyclic; R10 is selected from the group consisting of hydrogen, (C1-C20) optionally substituted heteroalkyl (C1-C20) optionally substituted (C2-C20) optionally substituted heteroalkenyl, (C2-C20) optionally substituted alkenyl, (C2 C20) optionally substituted (C6 C20) optionally substituted heteroaryl (C3-C20) optionally substituted aryl (C7-C20) optionally substituted heteroaryl (C4-C20) optionally substituted (C3-C20) optionally substituted and an optionally substituted cycloheteroalkyl (C2-C20); R represents hydrogen, (C1-C6) alkyl or (C1-C6) alkenyl or substituted or unsubstituted aryl (C6-C10) or OCOR10; R1 and R2 are each a hydrogen or R1 and R2 together form a single bond; R3, R4, Y1, Y2, Y3 are independently selected from the group consisting of H, halogen, -OH, O-alkyl, O-acetyl, -O-aryl, OC (O) R10, -SO2-R10 and -NHR10 , or together they form oxo (= O), or hydroxylamino alkoxyimine or aryloxyimine, thioacete; or R3 and R4 or Y1 and Y2 form a heterocyclic residue selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, thiazolidinyl, oxazolidinyl, morpholino, piperazinyl, 4-alkylpiperidinyl (C1-C4) and N-piperazinyl (C1-C4); and said alkyl, phenyl and naphthyl groups may be substituted with one or more residues selected from the group consisting of (C1-C8) alkyl, halogen, nitro, amino, azido and (C1-C8) alkoxy; R5 is selected from the group consisting of an optionally substituted (C1-C20) alkyl, optionally substituted heteroalkyl (C1-C20), optionally substituted alkenyl (C2-C20), optionally substituted heteroalkenyl (C2-C20), alkynyl (C2-C20) ) optionally substituted, optionally substituted aryl (C6-C20), optionally substituted heteroaryl (C3 C20), optionally substituted arylalkyl (C7-C20), optionally substituted heteroarylalkyl (C4-C20), optionally substituted cycloalkyl (C3-C20), cycloheteroalkyl ( C2-C20) optionally substituted, N (R8) (R9); -OR10, -SR10, -N (R8) -C (O) R10, -N (R8) -C (O) -OR10, -N (R8) -C (O) -NR8R10, N (R8) -C (S) OR10, -N (R8) -C (S) -OR10 and -N (R8) -C (S) -NR8R10; R6 is selected from the group consisting of hydrogen, halogen, a (C1-C10) alkyl, (C1-C10) alkenyl, optionally substituted or unsubstituted aryl (C6-C10); and R7 is selected from the group consisting of hydrogen, an optionally substituted (C1-C10) alkyl, optionally substituted aryl (C5 C10) and optionally substituted acyl (C1-C10). |
| priorityDate | 2006-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 219.